HARA-B Cells
CAD$545.10*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | The HARA-B cell line is derived from human squamous cell carcinoma of the lung, specifically established from metastatic bone tissue in a mouse model. This cell line is a secondary development from the original HARA cell line and is characterized by its high expression of parathyroid hormone-related protein (PTHrP), which plays a significant role in the extensive bone metastasis observed in these cells. The HARA-B line has been instrumental in studying the mechanisms of bone metastasis associated with lung cancer. Scientific studies involving HARA-B often focus on its utility in modeling hypercalcemia, a common paraneoplastic syndrome associated with certain cancers, including lung cancer. The hypercalcemia in this model is induced by hypodermic transplantation of the cells, providing a valuable tool for understanding the interactions between cancer cells and bone cells, as well as the pathways that lead to bone degradation and calcium release. This cell line helps researchers investigate potential therapeutic strategies to mitigate bone metastasis and associated complications in lung cancer patients. |
|---|---|
| Organism | Human |
| Tissue | Lung |
| Disease | Lung squamous cell carcinoma |
| Metastatic site | Pleural effusion |
| Synonyms | HARAB |
Characteristics
| Age | 57 years |
|---|---|
| Gender | Male |
| Ethnicity | Japanese |
| Growth properties | Adherent |
Regulatory Data
| Citation | HARA-B (Cytion catalog number 300465) |
|---|---|
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_2915 |
Biomolecular Data
| Protein expression | Produces high level of parathyroid hormone-related peptide (PTHrP). |
|---|
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | Accutase |
| Subculturing | Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium. |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 300465-230224 | Certificate of Analysis | 23. May. 2025 | 300465 |
| 300465-200525 | Certificate of Analysis | 21. Jul. 2025 | 300465 |